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ABSTRACT
BACKGROUND AND PURPOSE: Deep gray matter involvement is a consistent feature in multiple sclerosis. The aim of this study was to
evaluate the relationship between different deep gray matter alterations and the development of subcortical atrophy, as well as to
investigate the possible different substrates of volume loss between phenotypes.
MATERIALS AND METHODS: Seventy-seven patients with MS (52 with relapsing-remitting and 25 with progressive MS) and 41 healthy
controls were enrolled in this cross-sectional study. MR imaging investigation included volumetric, DTI, PWI and Quantitative Suscepti-
bility Mapping analyses. Deep gray matter structures were automatically segmented to obtain volumes and mean values for each MR
imaging metric in the thalamus, caudate, putamen, and globus pallidus. Between-group differences were probed by ANCOVA analyses,
while the contribution of different MR imaging metrics to deep gray matter atrophy was investigated via hierarchic multiple linear
regression models.
RESULTS: Patients withMS showed amultifaceted involvement of the thalamus and basal ganglia, with signiﬁcant atrophy of all deep gray
matter structures (P .001). In the relapsing-remitting MS group, WM lesion burden proved to be the main contributor to volume loss for
all deep gray matter structures (P .006), with a minor role of local microstructural damage, which, in turn, was the main determinant of
deep gray matter atrophy in patients with progressive MS (P .01), coupled with thalamic susceptibility changes (P .05).
CONCLUSIONS: Our study conﬁrms the diffuse involvement of deep graymatter inMS, demonstrating a different behavior betweenMS
phenotypes, with subcortical GM atrophy mainly determined by global WM lesion burden in patients with relapsing-remitting MS, while
local microstructural damage and susceptibility changes mainly accounted for the development of deep gray matter volume loss in
patients with progressive MS.
ABBREVIATIONS: DDdisease duration; DGMdeep graymatter; DMTdisease-modifying treatment; EDSS ExpandedDisability Status Scale; FA fractional
anisotropy; HC healthy controls; LL lesion load; MDmean diffusivity; PMS progressive MS; QSMQuantitative Susceptibility Mapping; rCBV relative CBV;
RRMS relapsing-remitting MS
Deep gray matter (DGM) involvement is generally regarded asa consistent feature inMS, generating particular interest due
to its clinical relevance.1
Indeed, the occurrence of DGM atrophy in these patients, of-
ten described as an early phenomenon,2,3 has been proved by several
volumetric MR imaging studies, with a significant correlation with
clinical disability, cognition, and disease progression.3-5
Along with volume loss, a wide range of pathologic changes
affecting the DGM of patients with MS has been also demon-
strated using different advanced MR imaging techniques. In par-
ticular, DTI studies showed the presence of microstructural
damage in these structures,6-9 while PWI and Quantitative
Susceptibility Mapping (QSM) studies described decreased cerebral
perfusion10-13 and a complex pattern of susceptibility changes14-17
affecting the DGM of patients with MS, respectively.
Although atrophy most certainly reflects neuronal loss, the
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deed, DGM volume loss could be either due to the occurrence of
primary local pathology or secondary toWM inflammatory dam-
age, leading to Wallerian degeneration and deafferentation.18,19
From this background and despite the relatively wide knowledge
about the multifaceted involvement of DGM in MS, a study si-
multaneously investigating the contribution to the development
of subcortical GM atrophy of these different physiopathologic
changes is, to date, lacking.
We therefore collected different MR imaging variables related
to distinct aspects of DGM damage in patients with both relaps-
ing-remittingMS (RRMS) and progressive MS (PMS), to investi-
gate the relationship between these alterations and the develop-
ment of subcortical GM atrophy, as well as the possible different




In this single-center observational study, 77 patients with MS (52
RRMS and 25 PMS according to the 2013 revised definition ofMS
phenotypes20) and 41 healthy controls (HC) were enrolled from
October 2013 to July 2015 in a neuroimaging study of neuroin-
flammatory disorders.21,22 All patients with MS fulfilled the 2010
revisedMcDonald criteria,23 while none of theHCpresentedwith
any condition that could affect the CNS. For all patients, the Ex-
panded Disability Status Scale (EDSS) score was determined
within 1 week fromMR imaging by an experienced neurologist as
an index of clinical disability, along with the record of disease
duration (DD) and disease-modifying treatment (DMT) type
(On-line Table 1).
Demographic and clinical characteristics of all subjects in-
cluded in the analysis are provided in Table 1.
Standard Protocol Approvals, Registrations, and Patient
Consents
The protocol was approved by the “Carlo Romano” ethics com-
mittee for biomedical activities of “Federico II,” University of
Naples, and written informed consent was obtained from all par-
ticipants before the beginning of the study in accordance with the
Declaration of Helsinki.
MR Imaging Data Acquisition and Processing
A complete description of all the acquired sequences, along with
all processing procedures, is available in the On-line Appendix.
Briefly, the acquisition protocol included a 3D T1-weighted
sequence used for volumetric analyses, a 3D-FLAIR sequence for
the quantification of demyelinating lesion load (LL) volume, an
echo-planar imaging sequence for the dynamic susceptibility con-
trast–PWI analysis, an unenhanced 3D double-echo FLASH se-
quence for the calculation of QSMmaps, and, in a subgroup of 59
patients (38 RRMS, 21 PMS) and 38 HC, an echo-planar imaging
sequence for DTI analysis.
DGM segmentation was achieved using the FIRST routine
(FMRIB Integrated Registration and Segmentation Tool; http://
fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST) implemented in FSL, Ver-
sion 5.0.10; the latterwas also used to extract fractional anisotropy
(FA) and mean diffusivity (MD) maps from the DTI datasets.
PWI data were analyzed using Olea Sphere software, Version 2.3
(Olea Medical, La Ciotat, France) to generate relative cerebral
blood volume (rCBV) and relative CBF maps. A complete de-
scription of all processing steps required for the calculation of
QSM images is available in Palma et al,24 Borrelli et al,25 and
Palma et al.26
For each subject, DTI, PWI, and QSMmaps were coregistered
to the 3D T1-weighted sequence via affine registration, and seg-
mentation masks were used to obtain DGM volumes and mean
values for each MR imaging metric (Fig 1).
Statistical Analysis
Distribution of all datawas preliminarily checkedwith graphs and
tests (ie, the Levene test for homoscedasticity and the Kolmogo-
rov-Smirnov test for normality), and those variables showing a
significantly skewed distribution (namely, LL) were normalized
by log-transformation.
Group differences were probed by the Student t (age, DD),
Pearson 2 (sex, DMT), and Mann-Whitney (EDSS) tests, while
differences inMR imagingmetrics were tested by ANCOVA anal-
yses, including age, sex, and DD (when comparing MS sub-
groups) as covariates.
To determine the main contributors to subcortical GM atro-
phy in patients with MS, we conducted analyses as follows. For
each DGM structure, the relationship between advanced MR im-
aging metrics and the respective normalized volume was prelim-
inarily investigated using partial correlation analyses (age-, sex-,
and DD-corrected) in the whole MS population and within the
different subgroups. Variables showing a significant correlation
with DGM volume loss were entered in the third and final step of
each hierarchic multiple linear regression analysis, in which vol-
ume was set as the dependent variable and clinical and demo-
graphic variables (age, sex, DD, and type ofDMT)were entered in
the first block and LL in the second step.
Finally, to explore the potential additional value of multiple
MR imaging parameters for the prediction of clinical disability
Table 1: All subjects’ demographics and clinical variablesa
MS HC
P Value
(MS vs HC) PMS RRMS
P Value
(PMS vs RRMS)
Age 41.2 11.0 43.6 13.9 .34 43.7 11.8 40.0 10.6 .17
Sex 33 F/41 M 20 F/21 M .54 10 F/15 M 23 F/29M .73
DD 12.1 7.6 NA NA 14.3 7.6 11.1 7.5 .09
EDSS 3.5 (2.0–7.5) NA NA 5.5 (3.0–7.5) 3.5 (2.0–6.0) .001b
DMT 71/77 (92.2%) NA NA 22/25 (88.0%) 49/52 (94.2%) .34
Note:—NA indicates not applicable.
a Age and DD (in years) are expressed as mean SD; EDSS, as median (range).
b Signiﬁcant difference.
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in all groups, we also preliminarily investigated the relation-
ship between the EDSS score and DGM metrics that proved to
be significantly different between patients with MS and HC via
partial correlation analyses (age-, sex-, and DD-corrected).
MR imaging metrics showing a significant correlation with
EDSS were then entered in the fourth and final block of a
hierarchic multiple linear regression analysis for the prediction
of clinical disability, including clinicodemographic variables
in the first step, LL in the second block, and DGM volumes in
the third step, with the same analysis also probed within dif-
ferent MS subgroups.
All analyseswere performedwith the Statistical Package for the
Social Sciences, Version 24 (IBM, Armonk, New York), with a
significance level set at P .05, Bonferroni-corrected formultiple
comparisons. For the regression analyses, multiple-comparison
correction was adopted for the models only, while independent
predictors were considered significant at P .05.
Data Availability
Anonymized data will be shared by request from any qualified
investigator.
RESULTS
Demographic and Clinical Findings
TheMSandHCgroups did not significantly differ in age (P .34)
and sex (P .54). Similarly, when we compared PMS and RRMS,
the 2 subgroups did not show any significant difference in terms
of age (P .17), sex (P .73), DD (P .09), or DMT (P .34),
with patients with progressive MS showing a more severe clinical
impairment compared with those with RRMS (P .001).
Between-Group MR Imaging Analysis
A complete list of the results of the between-group analysis re-
garding MR imaging metrics is available in Table 2.
Compared with HC, patients with MS showed a significant
reduction of all brain volumes (all with P .001), with the PMS
subgroup presenting with a slightly higher lesion load compared
with the RRMS group (P  .03, not significant after Bonferroni
correction), while no differences emerged between phenotypes in
terms of brain tissue volumes.
A significant atrophy of both the thalamus and basal ganglia
was found in MS compared with HC (all with P  .001), with
increasedMDvalues in patients at the level of caudate nucleus and
thalamus (P .001) and a trend toward increased FA in the pu-
tamen (P  .02, not significant after Bonferroni correction). Fi-
nally, patients showed a reduction of susceptibility values in the
thalamus compared with HC (P  .001), while no differences
emerged for PWI measures.
When possible differences between MS phenotypes were
probed, PMS compared with RRMS showed a significant volu-
metric reduction of the thalamus (P .005), caudate (P .007),
globus pallidus (P  .001), and, to a lesser extent, the putamen
(P  .02, not significant after Bonferroni correction), with bor-
derline higher MD (P .05, not significant after Bonferroni cor-
rection), significantly reduced rCBV values (P .002) at the level
of the caudate nucleus, and a trend toward higher FA in the pu-
tamen (P .05, not significant after Bonferroni correction).
Partial Correlation Analyses
A complete list of all the results obtained from the preliminary
correlation analyses is available in the On-line Appendix and cor-
responding On-line Tables 2 and 3.
Relationship between Advanced MR Imaging Metrics and
DGM Volumes
A list of the results of the regression analyses investigating the
relations between advanced MR imaging metrics and DGM vol-
umes in patients with MS as well as within different subgroups is
reported in Tables 3 and 4, respectively.
The regression analysis conducted on the entire MS group
showed that LL (all with P  .02) and microstructural GM
FIG 1. Results of the coregistration between different MR imaging modalities (upper row), with superimposed deep gray matter masks (lower
row). From left to right, 3D T1-weighted volume, fractional anisotropy, mean diffusivity, relative cerebral blood volume, relative cerebral blood
ﬂow, and Quantitative Susceptibility Mapping images.
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changes (all with P  .001) were independent predictors of vol-
ume loss for the investigated DGM structures, with an additional
significant contribution of susceptibility changes to the develop-
ment of thalamic volume loss (P .007).
When the regression analyses were probed in the different MS
phenotypes, LL proved to be a constant independent predictor of
volume loss for all the DGM structures in the RRMS group (all
with P  .006), with an additional and relative contribution of
localmicrostructural GMchanges in the development of thalamic
(P  .02) and caudate (P  .04) atrophy. On the other hand,
microstructural damage was themain determinant of DGM atro-
phy in patients with PMS (all with P .01) without a significant
value of global MR imaging measures but coupled with suscepti-
bility changes in the development of volume loss at the level of the
thalamus (P .05).
Scatterplots of the relationships between DGM volumes and
significantMR imaging predictors in patients withMS andwithin
the different subgroups are shown in Figs 2 and 3, respectively.
Relationship between DGMMetrics and Clinical Disability
The regression analysis showed that the only independent predic-
tor of clinical disability in the MS group was thalamic volume
(standardized0.306, P .02), which explained, in addition
to clinicodemographic variables and LL, 32.2% of the variance of
the EDSS (R2 5.6%, P .001) without incremental explana-
tion of the variance provided by other advanced MR imaging
measures (On-line Table 4). No significant differences between
RRMS and PMS emerged in the same analysis.
DISCUSSION
In this study, we used a multimodal MR imaging approach to
investigate different features of DGM involvement in MS, con-
firming the presence of a diffuse andmultifaceted involvement of
subcortical GM structures in this condition. We demonstrated
thatWM lesion burden represents themain determinant of DGM
atrophy inRRMS,with a concomitant though relative role of local
microstructural damage, which, in turn, proved to be the main
Table 2: MRI metrics for all subjects included in the analysisa
MS HC P Value (MS vs HC) PMS RRMS P Value (PMS vs RRMS)
LL 13.8 16.2 NA NA 18.3 16.7 11.6 15.7 .03c
NBV 1467.8 86.9 1547.2 67.7 .001b 1440.0 101.7 1481.2 76.3 .17
NGMV 745.8 60.4 793.5 54.8 .001b 724.7 66.3 755.9 55.3 .09
NWMV 722.0 36.6 753.6 27.6 .001b 715.3 46.4 725.3 30.7 .31
DGM Volumes
Thalamus 18.7 2.6 21.9 2.1 .001b 17.4 3.1 19.4 2.1 .005b
Caudate 8.4 1.4 9.5 1.2 .001b 7.7 1.6 8.7 1.1 .007b
Putamen 12.3 1.8 13.8 1.8 .001b 11.5 1.3 12.9 1.5 .02c
Globus pallidus 4.5 0.7 5.0 0.6 .001b 4.1 0.8 4.6 0.5 .001b
DGM Diffusion
MD thalamus 0.95 0.09 0.88 0.06 .001b 0.98 0.11 0.96 0.11 .25
MD caudate 1.00 0.10 0.92 0.08 .001b 1.04 0.10 0.98 0.10 .05c
FA putamen 0.272 0.024 0.263 0.019 .02c 0.282 0.029 0.267 0.020 .05c
DGM Perfusion
rCBV caudate 2.8 1.0 3.1 1.0 .12 2.3 1.0 3.0 0.9 .002b
DGM Susceptibility
 thalamus 26.8 31.4 7.7 22.4 .001b 38.7 31.4 21.1 30.1 .14
Note:—NBV indicates normalized brain volume; NGMV, normalized gray matter volume; NWMV, normalized white matter volume; NA, not applicable.
a Values are expressed as means SD (volume in milliliters, MD in103 mm2/s, rCBV in milliliters/100 mL, FA is a scalar value between 0 and 1,  is in parts per billion).
b Signiﬁcant difference.
c Not signiﬁcant after Bonferroni correction.
Table 3: Results of the analyses exploring the relationship between MRI measures and DGM volume in the entire MS group
DGM Volumes
Model Predictor
R2 (R2) F (F) P Value Standardized  T P Value
Thalamus 0.679 (0.320) 13.266 (21.902) .001
DMT 0.205 2.189 .03
LL 0.347 3.383 .002
MD thalamus 0.515 4.738 .001
 thalamus 0.295 2.818 .007
Caudate 0.609 (0.297) 11.337 (19.351) .001
DMT 0.265 2.729 .009
LL 0.279 2.696 .009
MD caudate 0.422 4.122 .001
FA caudate 0.494 5.255 .001
Putamen 0.445 (0.187) 6.944 (17.546) .001
DMT 0.272 2.429 .02
LL 0.278 2.367 .02
FA putamen 0.516 4.189 .001
Globus pallidus 0.300 (0.183) 6.078 (18.557) .001
DMT 0.358 3.332 .001
LL 0.481 4.308 .001
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contributor to the development of subcortical GM volume loss in
PMS, along with thalamic susceptibility changes.
In accordance with the great corpus of scientific literature that
describes subcortical GM atrophy as an early and consistent fea-
ture ofMS, strictly linkedwith disease course and clinical progres-
sion,2-5 we found significant DGM atrophy in our group of pa-
Table 4: Results of the analyses exploring the relationship between MRI measures and DGM volume in the MS subgroups
DGM Volumes
Model Predictor
R2 (R2) F (F) P Value Standardized  T P Value
RRMS
Thalamus 0.750 (0.081) 6.637 (5.738) .001
DMT 0.289 2.313 .03
LL 0.454 3.214 .003
MD thalamus 0.371 2.395 .02
Caudate 0.563 (0.061) 6.662 (4.346) .001
DMT 0.352 2.702 .01
LL 0.411 2.938 .006
MD caudate 0.287 2.085 .04
Putamen 0.662 (0.196) 7.187 (16.073) .001
DMT 0.497 4.166 .001
LL 0.502 4.009 .001
Globus pallidus 0.611 (0.158) 5.484 (11.608) .001
DMT 0.487 3.868 .001
LL 0.450 3.407 .001
PMS
Thalamus 0.832 (0.585) 7.761 (19.119) .001
MD thalamus 0.566 3.091 .01
 thalamus 0.493 2.233 .05
Caudate 0.799 (0.576) 7.362 (18.587) .001
FA caudate 0.783 5.789 .001
Putamen 0.580 (0.506) 3.228 (16.890) .03a
FA putamen 0.836 4.110 .001
a Not signiﬁcant after Bonferroni correction.
FIG 2. Scatterplotmatrix showing the correlations betweenDGMvolumes and their signiﬁcantMR imaging predictors in the regression analyses
in patients with MS.
AJNR Am J Neuroradiol 40:99–106 Jan 2019 www.ajnr.org 103
tients. This volume loss was more pronounced in PMS, a finding
also consistent with previous evidence,2 in line with the hypoth-
esis of a prominent role of neurodegenerative phenomena in the
pathophysiology of this phenotype.18,27
Furthermore, our results confirm the presence of microstruc-
tural damage in the DGM of patients with MS, mostly affecting
the caudate nuclei and thalami. These findings, also in substantial
accordance with previous evidence,6-9 can be considered as a re-
flection of microstructural damage due to demyelination and ax-
onal injury, which cause a net loss of structural barriers facilitating
water diffusion, while the increased FA might be explained by
extra-axonal phenomena such as the loss of dendritic connections
and/or the swelling of neuronal cell bodies.7,8
On the other hand, we failed to find significant alterations of
PWI parameters in patients with MS compared with HC, a result
in conflict with some previous studies in which decreased perfu-
sion of these structures was described.10-12,28,29 A possible expla-
nation for this discrepancy could reside in the different methodo-
logic approaches between our work (in line with those available in a
study analyzing PWIdatawith amethod similar to ours30) and these
previous studies conducted using hand-drawn ROIs11,28,29 (which
had operator dependencies) or voxel-based approaches10,12 (which
provide different, though complementary, information). Most
interesting, when we compared MS phenotypes, a reduction in
rCBV values of the caudate nuclei in patients with PMS compared
with RRMS was proved. Different mechanisms could explain this
finding, mainly related to a decreased neuronal metabolic de-
mand secondary to atrophy,13,30 though primary neuronal meta-
bolic dysfunctions and alterations of cerebral vasculature have
also been proposed.13,30
Finally, at the QSM analysis, patients with MS showed a sig-
nificant reduction of magnetic susceptibility values in the thala-
mus compared with HC, in line with recent quantitative MR im-
aging studies.14-17 The physiopathologic basis of this altered
susceptibility could reside in the variable association of reduced
paramagnetic components (ie, iron) and increased diamagnetic
components (ie, myelin and/or calcium). Thus, several hypothe-
ses have been proposed, including increasedmyelin density due to
GM loss, calcium deposition, and, in particular, iron depletion.
The latter could be an indirect consequence of tissue loss and/or
could result from an active process of iron removal fromdamaged
oligodendrocytes, related to chronic microglia activation, ulti-
mately leading to neurodegeneration.14-17
When investigating the contribution of different MR imaging
metrics to the development DGM atrophy in MS subgroups, we
found that a global MR imaging measure of WM damage
(namely, the LL) was a constant significant predictor of volume
loss for all DGM structures for the patients with RRMS, with an
additional, though relative, contribution of local microstruc-
tural GM changes in the development of thalamic and caudate
atrophy only. This result confirms a suggested possible role of
WM lesions in driving atrophy of the highly connected subcor-
tical GM structures, most likely through axonal transection
leading to disconnection, with a subsequent degeneration
along axonal projections.2,31
On the other hand, microstructural damage proved to be the
FIG 3. Scatterplot matrices of the correlations between DGM volumes and their signiﬁcant MR imaging predictors in the regression analyses in
patients with RRMS (A) and PMS (B).
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maindeterminant ofDGMatrophy in patientswith PMS,without
a significant role of LL, corroborating the role of localmicrostruc-
tural damage as a possible primary determinant of neuronal loss
and subsequent atrophy in subcortical GM.6-7
Furthermore, whenwe evaluated the determinants of thalamic
atrophy in PMS, a direct effect of the reduced susceptibility values
found in this structure on its volume was found, in apparent con-
trast with the common notion of iron increase as a possible driver
of neurodegeneration inMS.32 A possible explanation for this last
result could be found in the peculiar morphofunctional architec-
ture of the thalamus. Indeed, this structure, due to its rich con-
nectivity profile, shows a high oligodendrocyte density, being
more prone to secondary effects from remote injury in other areas
of the brain.17 Thus, a chronic microglial activation could lead to
thalamic oligodendroglial damage, with subsequent iron release,
generating, in turn, a vicious cycle reducing axonal protection and
neuronal repair, eventually leading to neurodegeneration.17
All these results, taken together, support the hypothesis that
different MS phenotypes could be characterized by distinct phys-
iopathologicmechanisms, with amore prominent role of primary
GMpathology in patients with PMS,which occurs, at least in part,
independent from global WM lesion burden.1,19,27
Finally, we explored the clinical impact of these DGM altera-
tions, proving that thalamic volume was the only significant pre-
dictor of EDSS score, without any additional value provided by
the other tested MR imaging measures. This result confirms and
expands the current knowledge about the clinical relevance of
thalamic atrophy in MS, which could represent a common path-
way through which both WM lesions and local DGM pathology
contribute to clinical disability.3-5,33 Indeed, the thalamus is in-
volved in all themajor functional circuits in the brain, providing a
point of convergence across multiple cortical, limbic, brain stem,
and cerebellar systems; therefore, it is easy to understand how its
volume loss could represent one of the most clinically relevant
biomarkers of disease in MS.33
Some limitations of the present study should be acknowl-
edged. In particular, additional physiopathologic information on
DGM structures could have been obtained using other advanced
MR imaging techniques (eg, magnetization transfer ratio, MR
spectroscopy, or functional MR imaging) or with voxelwise ap-
proaches, while a longitudinal evaluation could have helped un-
ravel the causal relationships among different aspects of DGM
pathology as well as between subcortical GM alterations and clin-
ical disability. Thus, future studies are warranted simultaneously
investigating the role of additional different aspects of DGM pa-
thology and their evolution with time, coupled with more exten-
sive neurologic and neuropsychological examinations, to further
expand our knowledge of the physiopathology and the clinical
relevance of DGM damage in MS.
CONCLUSIONS
Our study provides additional information about DGM involve-
ment in patients with MS, showing the presence of alterations of
different MR imaging metrics as a possible reflection of neurode-
generative and neuroinflammatory processes in these structures.
Furthermore, our results demonstrate the presence of a different
behavior of DGM atrophy in MS phenotypes, with subcortical
GM volume loss mainly determined by global WM lesion burden
in patients with RRMS,while localmicrostructural damage, along
with susceptibility changes, account for the development of the
significant DGM atrophy occurring in patients with PMS.
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